Tamoxifen Citrate Issued Labeling Change: Page 2 of 2 from buzai232's blog
SignTheLine
Tamoxifen Citrate Issued Labeling Change: Page 2 of 2 Soltamox is an oral solution indicated for adult women with early stage estrogen receptor-positive metastatic breast cancer or as adjuvant treatment for breast cancer. Soltamox can also be used to reduce the risk of invasive breast cancer following breast surgery and radiation in adult women with ductal carcinoma in situ (DCIS), and to reduce the incidence of breast cancer in high-risk patients. The drug is not recommended for women who have already developed breast cancer, because serious life-threatening risks including uterine malignancies, stroke, and pulmonary embolism which outweigh any potential benefits of the drug. Women with metastatic breast cancer should take between 20 mg and 40 mg of the drug per day, with dosages higher than 20 mg to be split evenly between morning and evening. If prescribed for the adjuvant treatment of breast cancer, DCIS, or the reduction of breast cancer, dosages should not exceed 20 mg per day.https://www.aasraw.com/products/tamoxifen-citrate-nolvadex-powderSoltamox is contraindicated for patients with known hypersensitivity to tamoxifen or any other Soltamox ingredients, patients who require concomitant warfarin therapy, those with a history of deep vein thrombosis or pulmonary embolism, and if the reason for use includes reduction of breast cancer in high-risk patients or after DCIS treatment. Some of the most common adverse events reported while using Soltamox include hot flashes, mood disturbances, vaginal discharge, vaginal bleeding, nausea, and fluid retention.
The Wall